Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Josef S SmolenMark C GenoveseTsutomu TakeuchiDavid L HyslopWilliam L MaciasTerence RooneyLei ChenChristina L DicksonJennifer Riddle CampTracy E CardilloTaeko IshiiKevin L WinthropPublished in: The Journal of rheumatology (2018)
In this integrated analysis of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy. Trial registration numbers: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078 at clinicaltrials.gov.